BioMarin Announces Global Settlement with Ascendis Pharma A/S; Ascendis Will Pay Royalties to BioMarin on Yuviwel Sales in U.S., EU, Brazil and South Korea
BioMarin reached a global settlement with Ascendis Pharma that ends all pending patent proceedings and gives BioMarin royalties on Yuviwel sales in the U.S., EU, Brazil and South Korea. The agreement removes a legal overhang for BMRN, but the specific royalty rates and expected financial contribution remain undisclosed, leaving the market without enough detail for a strong earnings read.
BioMarin announced Aug. 30 that it entered binding terms with Ascendis Pharma A/S to resolve all pending patent-related proceedings between the companies. Under the agreement, Ascendis will pay BioMarin royalties tied to Yuviwel sales in the U.S., EU, Brazil and South Korea.
The settlement changes the status of a dispute that had left the commercial and legal outlook for Yuviwel subject to patent proceedings. Instead of continuing across the affected markets, the matter will be governed by the agreed royalty arrangement. The specific royalty rates, payment timing, sales milestones and revenue estimates remain confidential.
For BioMarin, the direct connection is to future royalty revenue rather than the company's existing product sales. The company reported FY 2025 revenue of $3.2B, up 12.9% YoY, along with a 10.8% net margin and $1.80 diluted EPS. How the Yuviwel payments will affect those figures is unclear.
Ascendis is the commercial party responsible for Yuviwel sales in the four named territories, while BioMarin receives the contractual royalty stream. The patent claims covered, the duration of the royalties, the settlement's accounting treatment and any restrictions on commercialization have not been specified.
The missing detail limits the immediate financial interpretation. The agreement resolves the proceedings, but the size and timing of the economic benefit remain unclear. The next useful disclosures would be the complete settlement terms, BioMarin's treatment of the royalties in guidance or filings, and reported Yuviwel sales in the U.S., EU, Brazil and South Korea. Until those figures are available, the settlement is a clearer legal outcome than an earnings estimate.
The settlement removes patent uncertainty and adds an undisclosed royalty stream, modestly improving the setup for BMRN without yet changing the earnings case.
The immediate consequence is a cleaner legal path and potential incremental revenue for BMRN, but the economic value cannot be sized because the release omits royalty rates, timing and Yuviwel sales. That makes the read constructive but insufficiently quantified for a conviction trade.
The settlement could have limited royalty economics, and the absent terms may fail to improve BioMarin’s reported revenue or earnings materially.
CoverageSource: PR Newswire · Published here MON, AUG 31 · 7:03 AM ET · 2 reports · 2 publishers in this record · latest listed: GlobeNewswire · MON, AUG 31 · 7:03 AM ETHow this is decided →
PR NEWSWIRE / FILEEarlier context and later coverage are dated relative to this report. Automatically linked reports may cover a broader event.
No later reports linked yet.
Follow this story to find new evidence in your Following desk.
Price context does not establish that the story caused the move.
BMRN combines a resolved patent dispute with a new royalty stream against a business that reported $3.2B of FY 2025 revenue, up 12.9% YoY.
The settlement’s financial benefit remains unproven because no royalty rate, payment schedule or Yuviwel sales figure was disclosed.
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · nothing here is advice · How the Wire is made →